Italian Registry to Study Cardiovascular Effects and Outcomes in Anderson-Fabry Disease Patients Aged 2 Years and Older
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-02-04
800
Participants Needed
54
Research Sites
47 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting the RICMAF Study, an observational, multicenter, non-drug study in Italy focused on Anderson-Fabry Disease AFD, a rare genetic disorder that affects multiple organs, especially the heart. The study aims to better understand AFDs clinical course, its cardiac complications, and the relationship between genetic mutations and disease progression. This research seeks to improve patient care by identifying early markers of heart involvement and predicting cardiovascular problems.
The study collects data from patients diagnosed with AFD according to international guidelines, starting from January 1, 1981, through December 31, 2031. It includes both retrospective and prospective phases, gathering comprehensive clinical, genetic, laboratory, and imaging information through a national patient registry. Patients undergo regular assessments as part of their standard care, including cardiology evaluations, ECG, echocardiography, and cardiac MRI when appropriate.
Participants contribute data during routine clinical visits without additional study-specific procedures. The research team collects information from medical records and follow-up visits, including family history, symptoms, genetic tests, and heart monitoring results. The primary outcome is to define the natural history of Fabry disease over an average follow-up of five years, while secondary outcomes focus on cardiac risk stratification, genotype correlations, and early diagnostic biomarkers. The study duration extends up to 10 years, with ongoing data analysis and publication of findings.
CONDITIONS
Brief Title
Italian Anderson Fabry Disease Cardiovascular Registry
Research Team
E
Elena Biagini, MD, PhD
S
Silvia Palmieri, M. Sc.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lead Sponsor
Who Can Participate
Age: 2Years +
All Genders
Eligibility Criteria
You may qualify if you...
Patients diagnosed with Anderson Fabry disease
Age 2 years or older at diagnosis
Informed consent obtained from patient or parent/legal guardian
You will not qualify if you...
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Monitoring
Duration - Up to 10 years
Participants who undergo routine care for Anderson-Fabry Disease are observed. Clinical evaluations, instrumental investigations, and therapeutic interventions are performed as per standard care practices.
Annual cardiology evaluations and other specialist visits as clinically indicated
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Phase 12a Open-Label Study of 4D-310 Gene Therapy in Adults with Fabry Disease Affecting the Heart
Global Observational Study of Pregnant and Breastfeeding Women With Fabry Disease and Their Infants Evaluating Outcomes With and Without Migalastat Exposure
Observational Study of Elfabrio Safety and Effectiveness
in Adults with Fabry Disease Across Multiple Countries
Observing the Effects of Agalsidase Alfa Enzyme Replacement Therapy in Chinese Children and Adults With Fabry Disease in Everyday Clinical Use
Evaluating 12-Month Migalastat Treatment in Children Aged 2 to Under 12 Years with Fabry Disease and Responsive GLA Variants
Open-Label Multicenter Study on Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy
Observational Study Evaluating Long-Term Outcomes and Quality of Life in Patients With Fabry Disease Treated With Migalastat or Enzyme Replacement Therapy
Evaluating Safety and Effects of Replagal Infusions in Indian Children and Adults with Fabry Disease
Study of PRX-102 Enzyme Replacement Therapy in Children and Adolescents Ages 2 to 17 With Fabry Disease to Assess Safety and Effects
Open-label Trial Evaluating Lucerastat Safety and Efficacy in Untreated Adult Male Fabry Disease Patients
Fitness Improvement Training for Adults with Anderson-Fabry Disease A 12-Week Physiotherapy Exercise Program Compared to No Intervention
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.